Results of a multicenter phase I/II trial of abiraterone acetate plus BEZ235 in metastatic, castration-resistant prostate cancer (mCRPC).

e16042 Background: Prostate cancer progression and development of resistance to abiraterone acetate (AA) is associated with loss of PTEN-mediated negative regulation of the PI3K and mammalian targe...